Jones Paul W, Nadeau Gilbert, Small Mark, Adamek Lukasz
Clinical Science, St George's, University of London, London, United Kingdom.
Respiratory Centre of Excellence, GSK, Uxbridge, United Kingdom.
Respir Med. 2014 Jan;108(1):129-35. doi: 10.1016/j.rmed.2013.08.015. Epub 2013 Aug 30.
GOLD proposed a COPD assessment framework focussed on symptoms measured by the COPD Assessment Test™ (CAT) or the mMRC and on exacerbation risk based on poor lung function (FEV1 <50%) or a history of ≥2 exacerbations in the previous year. This analysis examined the characteristics of COPD patients recruited from routine clinical settings and classified using the GOLD framework. 1041 European COPD patients (38.5% from primary care) from the Adelphi Respiratory Disease Specific Programme with information on CAT, mMRC, spirometry and exacerbation history in the previous year were analysed. Their mean age was 64.9 ± 9.9 years and mean FEV1 was 62.5 ± 17.8% predicted; 80% were in GOLD 2 spirometric grade or milder. CAT and mMRC cut points identified different groups of patients; using CAT, the composition was: Group A 9.3%, Group B 48.5%, Group C 0.7% and Group D 41.5%. 80% were classified as high risk based on exacerbation history and 25% of patients in a low risk category (GOLD A and B) had 1 exacerbation in the previous year. The incidence of diabetes, hypertension and hyperlipidaemia rose with worsening GOLD group (all p < 0.0001); diabetes GOLD A 4%, GOLD B 16%, GOLD D 29%; hypertension GOLD A 38%, GOLD B 55%, GOLD D 65%; hyperlipidaemia GOLD A 13%, GOLD B 30%, GOLD D 37%. In patients seen in routine clinical settings, 25% of GOLD low risk patients had one exacerbation per year and the incidence of cardio-vascular and metabolic diseases increases with worsening GOLD group.
慢性阻塞性肺疾病全球倡议(GOLD)提出了一个慢性阻塞性肺疾病评估框架,该框架侧重于通过慢性阻塞性肺疾病评估测试™(CAT)或改良英国医学研究委员会(mMRC)呼吸困难量表测量的症状,以及基于肺功能差(第1秒用力呼气容积[FEV1]<50%)或前一年≥2次加重病史的加重风险。本分析研究了从常规临床环境中招募并使用GOLD框架分类的慢性阻塞性肺疾病患者的特征。对来自阿德尔菲呼吸系统疾病专项计划的1041名欧洲慢性阻塞性肺疾病患者(38.5%来自初级保健)进行了分析,这些患者有关于CAT、mMRC、肺量计以及前一年加重病史的信息。他们的平均年龄为64.9±9.9岁,平均FEV1为预测值的62.5±17.8%;80%处于GOLD 2级肺量计分级或更轻级别。CAT和mMRC的切点确定了不同组别的患者;使用CAT时,分组情况为:A组9.3%,B组48.5%,C组0.7%,D组41.5%。根据加重病史,80%被分类为高风险,低风险类别(GOLD A和B)中的25%患者在前一年有1次加重。糖尿病、高血压和高脂血症的发生率随GOLD组病情加重而上升(所有p<0.0001);糖尿病在GOLD A组为4%,GOLD B组为16%,GOLD D组为29%;高血压在GOLD A组为38%,GOLD B组为55%,GOLD D组为65%;高脂血症在GOLD A组为13%,GOLD B组为30%,GOLD D组为37%。在常规临床环境中就诊的患者中,25%的GOLD低风险患者每年有1次加重,心血管和代谢疾病的发生率随GOLD组病情加重而增加。